ArticleBlood transfusion = Trasfusione del sangue2016
The role of ABO blood groups in Crohn's disease and in monitoring response to infliximab treatment.
Article in Blood transfusion = Trasfusione del sangue, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03644901 (Investigating the Role of ABO Blood Group in the Response to the Nonsurgical Periodontal Treatment.), which is not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigating the Role of ABO Blood Group in the Response to the Nonsurgical Periodontal Treatment.
Who cites it
7 citing papers in PubMed, 8 citations in OpenAlex.
- ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes.Frontiers in medicine · 2026Review
- ABO Blood Type and Clinical Characteristics Among Japanese Patients With Ulcerative Colitis.Cureus · 2024Article
- Associations Between ABO Blood Groups and Diseases in the Digestive System and Vein.International journal of general medicine · 2024Article
- Blood group as a novel predictor of postoperative atrial fibrillation after off-pump coronary artery bypass grafting.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Association between ABO blood group and risk of Crohn's disease: A case-control study in the Chinese Han population.Journal of clinical laboratory analysis · 2022Article
- ABO blood type and clinical characteristics of patients with ulcerative colitis: A hospital-based study in central Taiwan.PloS one · 2022Article
- The potential use of ABO blood group system for risk stratification of COVID-19.Medical hypotheses · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe variation in ABO blood groups is reported to be associated with multiple diseases. Infliximab (IFX) has been widely used in the treatment of Crohn's disease (CD). We aim to investigate the distribution of ABO blood groups in Chinese patients with CD and to explore its impact on response to IFX. MATERIALS AND
methodsPatients with CD were consecutively recruited to the study between 2007 and 2014. CD patients receiving IFX therapy were followed for at least two years.
resultsIn 293 patients with CD, most patients (40.6%) had blood type O (119/293). The odds ratio (OR) of CD in blood type O patients was 1.06 (95%CI: 0.6-1.86; p=0.84) compared to all other blood types. Among those CD patients, 107 patients received IFX treatment. One year after the first course of IFX, a significant association was found between the overall ABO system and outcomes of IFX treatment (p<0.001). CD patients with blood type AB (OR=4.42, 95% CI: 1.04-18.76; p=0.044) were more likely to achieve mucosal healing, while CD patients with blood type A had a high risk of losing response (OR=0.38, 95% CI: 0.15-0.96; p=0.040). DISCUSSION: ABO blood groups are not associated with prevalence of CD. Patients with blood type AB had a better response to IFX while those with blood type A appeared to have a risk of losing response to IFX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.